Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dendreon nets in $46mm through private sale

Executive Summary

Dendreon (immunotherapeutics for cancer) sold 8mm common shares at $5.92 apiece (a 24% premium) to an undisclosed institutional investor, netting about $46mm. The buyer also received seven-year warrants to purchase 8mm more shares at $20 each. Lazard was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies